Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ponesimod - Johnson & Johnson Innovative Medicine

Next Previous
Drug Profile

Ponesimod - Johnson & Johnson Innovative Medicine

Alternative Names: ACT-128800; Compound 8bo - Actelion; PONVORY; R-3477; RG 3477

Latest Information Update: 29 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Actelion Pharmaceuticals; Janssen Pharmaceuticals; Johnson & Johnson Innovative Medicine
  • Class Antipsoriatics; Chlorobenzenes; Imines; Phenyl ethers; Small molecules; Thiazolidines
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • No development reported Graft-versus-host disease
  • Discontinued Plaque psoriasis

Most Recent Events

  • 26 Mar 2024 Ponesimod licensed to Juvise Pharmaceuticals worldwide (excluding the USA and Canada)
  • 31 Jan 2024 US Patent and Trademark Office (USPTO) issues a notice of allowance for ponesimod for Multiple sclerosis
  • 16 Jan 2024 Actelion completes in the OPTIMUM-LT phase III trial for Multiple sclerosis in Belarus, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Finland, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, Mexico, Poland, Portugal, Romania, Russia, Serbia, Spain, Sweden, Turkey, Ukraine and United Kingdom (PO) (NCT03232073)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top